This Article Full Text Full Text (PDF) All Versions of this Article: 90/4/1929    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Apridonidze, T. Articles by Nestler, J. E. Search for Related Content PubMed PubMed Citation Articles by Apridonidze, T. Articles by Nestler, J. E. Related Collections Female Endocrinology Metabolism

Prevalence and Characteristics of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome

Departments of Internal Medicine (T.A., P.A.E., M.J.I., J.E.N.) and Obstetrics and Gynecology (J.E.N.), Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia 23298-0111

Address all correspondence and requests for reprints to: John E. Nestler, M.D., Medical College of Virginia, P.O. Box 980111, Richmond, Virginia 23298-0111. E-mail: nestler{at}hsc.vcu.edu.

The polycystic ovary syndrome (PCOS) is characterized by insulin resistance with compensatory hyperinsulinemia. Insulin resistance also plays a role in the metabolic syndrome (MBS). We hypothesized that the MBS is prevalent in PCOS and that women with both conditions would present with more hyperandrogenism and menstrual cycle irregularity than women with PCOS only.

We conducted a retrospective chart review of all women with PCOS seen over a 3-yr period at an endocrinology clinic. Of the 161 PCOS cases reviewed, 106 met the inclusion criteria. The women were divided into two groups: 1) women with PCOS and the MBS (n = 46); and 2) women with PCOS lacking the MBS (n = 60).

Prevalence of the MBS was 43%, nearly 2-fold higher than that reported for age-matched women in the general population. Women with PCOS had persistently higher prevalence rates of the MBS than women in the general population, regardless of matched age and body mass index ranges. Acanthosis nigricans was more frequent in women with PCOS and the MBS. Women with PCOS and the MBS had significantly higher levels of serum free testosterone (P = 0.002) and lower levels of serum SHBG (P = 0.001) than women with PCOS without the MBS. No differences in total testosterone were observed between the groups.

We conclude that the MBS and its components are common in women with PCOS, placing them at increased risk for cardiovascular disease. Women with PCOS and the MBS differ from their counterparts lacking the MBS in terms of increased hyperandrogenemia, lower serum SHBG, and higher prevalence of acanthosis nigricans, all features that may reflect more severe insulin resistance.

This article has been cited by other articles:

				A. J. Cussons, G. F. Watts, V. Burke, J. E. Shaw, P. Z. Zimmet, and B. G.A. Stuckey Cardiometabolic risk in polycystic ovary syndrome: a comparison of different approaches to defining the metabolic syndrome Hum. Reprod., October 1, 2008; 23(10): 2352 - 2358. [Abstract] [Full Text] [PDF]

				R. L. Thomson, J. D. Buckley, M. Noakes, P. M. Clifton, R. J. Norman, and G. D. Brinkworth The Effect of a Hypocaloric Diet with and without Exercise Training on Body Composition, Cardiometabolic Risk Profile, and Reproductive Function in Overweight and Obese Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3373 - 3380. [Abstract] [Full Text] [PDF]

				D. Romualdi, B. Costantini, L. Selvaggi, M. Giuliani, F. Cristello, F. Macri, A. Bompiani, A. Lanzone, and M. Guido Metformin improves endothelial function in normoinsulinemic PCOS patients: a new prospective Hum. Reprod., September 1, 2008; 23(9): 2127 - 2133. [Abstract] [Full Text] [PDF]

				L.P. Cheung, R.C.W. Ma, P.M. Lam, I.H. Lok, C.J. Haines, W.Y. So, P.C.Y. Tong, C.S. Cockram, C.C. Chow, and W.B. Goggins Cardiovascular risks and metabolic syndrome in Hong Kong Chinese women with polycystic ovary syndrome Hum. Reprod., June 1, 2008; 23(6): 1431 - 1438. [Abstract] [Full Text] [PDF]

				B. E. Johnson and J. Porter Preoperative Evaluation of the Gynecologic Patient: Considerations for Improved Outcomes Obstet. Gynecol., May 1, 2008; 111(5): 1183 - 1194. [Abstract] [Full Text] [PDF]

				D. S. Guzick Do Cardiovascular Risk Factors in Polycystic Ovarian Syndrome Result in More Cardiovascular Events? J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1170 - 1171. [Full Text] [PDF]

				N. Zhang, Y.-H. Shi, C.-F. Hao, H. F Gu, Y. Li, Y.-R. Zhao, L.-C. Wang, and Z.-J. Chen Association of +45G15G(T/G) and +276(G/T) polymorphisms in the ADIPOQ gene with polycystic ovary syndrome among Han Chinese women Eur. J. Endocrinol., February 1, 2008; 158(2): 255 - 260. [Abstract] [Full Text] [PDF]

				G. U. Liepa, A. Sengupta, and D. Karsies Polycystic Ovary Syndrome (PCOS) and Other Androgen Excess-Related Conditions: Can Changes in Dietary Intake Make a Difference? Nutr Clin Pract, February 1, 2008; 23(1): 63 - 71. [Abstract] [Full Text] [PDF]

				J. E. Nestler Metformin for the Treatment of the Polycystic Ovary Syndrome N. Engl. J. Med., January 3, 2008; 358(1): 47 - 54. [Full Text] [PDF]

				T. Cascella, S. Palomba, I. De Sio, F. Manguso, F. Giallauria, B. De Simone, D. Tafuri, G. Lombardi, A. Colao, and F. Orio Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndrome Hum. Reprod., January 1, 2008; 23(1): 153 - 159. [Abstract] [Full Text] [PDF]

				J. K Devin, J. E Johnson, M. Eren, L. A Gleaves, W. S Bradham, J. R Bloodworth Jr, and D. E Vaughan Transgenic overexpression of plasminogen activator inhibitor-1 promotes the development of polycystic ovarian changes in female mice J. Mol. Endocrinol., July 1, 2007; 39(1): 9 - 16. [Abstract] [Full Text] [PDF]

				F. Orio, F. Manguso, S. Di Biase, A. Falbo, F. Giallauria, D. Labella, A. Tolino, G. Lombardi, A. Colao, and S. Palomba Metformin administration improves leukocyte count in women with polycystic ovary syndrome: a 6-month prospective study Eur. J. Endocrinol., July 1, 2007; 157(1): 69 - 73. [Abstract] [Full Text] [PDF]

				Z. T. Bloomgarden Gut Hormones, Obesity, Polycystic Ovarian Syndrome, Malignancy, and Lipodystrophy Syndromes Diabetes Care, July 1, 2007; 30(7): 1934 - 1939. [Full Text] [PDF]

				M. Luque-Ramirez, F. Alvarez-Blasco, J. I. Botella-Carretero, E. Martinez-Bermejo, M. A. Lasuncion, and H. F. Escobar-Morreale Comparison of Ethinyl-Estradiol Plus Cyproterone Acetate Versus Metformin Effects on Classic Metabolic Cardiovascular Risk Factors in Women with the Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2453 - 2461. [Abstract] [Full Text] [PDF]

				T. Sir-Petermann, B. Echiburu, M M. Maliqueo, N. Crisosto, F. Sanchez, C. Hitschfeld, M. Carcamo, P. Amigo, and F. Perez-Bravo Serum adiponectin and lipid concentrations in pregnant women with polycystic ovary syndrome Hum. Reprod., July 1, 2007; 22(7): 1830 - 1836. [Abstract] [Full Text] [PDF]

				P. Sartorato, E. Zulian, S. Benedini, B. Mariniello, F. Schiavi, F. Bilora, G. Pozzan, N. Greggio, A. Pagnan, F. Mantero, et al. Cardiovascular Risk Factors and Ultrasound Evaluation of Intima-Media Thickness at Common Carotids, Carotid Bulbs, and Femoral and Abdominal Aorta Arteries in Patients with Classic Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency J. Clin. Endocrinol. Metab., March 1, 2007; 92(3): 1015 - 1018. [Abstract] [Full Text] [PDF]

				C. Vollmert, S. Hahn, C. Lamina, C. Huth, M. Kolz, A. Schopfer-Wendels, K. Mann, F. Bongardt, J. C. Mueller, F. Kronenberg, et al. Calpain-10 variants and haplotypes are associated with polycystic ovary syndrome in Caucasians Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E836 - E844. [Abstract] [Full Text] [PDF]

				K. Berneis, M. Rizzo, V. Lazzaroni, F. Fruzzetti, and E. Carmina Atherogenic Lipoprotein Phenotype and Low-Density Lipoproteins Size and Subclasses in Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., January 1, 2007; 92(1): 186 - 189. [Abstract] [Full Text] [PDF]

				R. Azziz, E. Carmina, D. Dewailly, E. Diamanti-Kandarakis, H. F. Escobar-Morreale, W. Futterweit, O. E. Janssen, R. S. Legro, R. J. Norman, A. E. Taylor, et al. Criteria for Defining Polycystic Ovary Syndrome as a Predominantly Hyperandrogenic Syndrome: An Androgen Excess Society Guideline J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4237 - 4245. [Abstract] [Full Text] [PDF]

				C. K. Welt, G. Arason, J. A. Gudmundsson, J. Adams, H. Palsdottir, G. Gudlaugsdottir, G. Ingadottir, and W. F. Crowley Defining Constant Versus Variable Phenotypic Features of Women with Polycystic Ovary Syndrome Using Different Ethnic Groups and Populations J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4361 - 4368. [Abstract] [Full Text] [PDF]

				F. Alvarez-Blasco, J. I. Botella-Carretero, J. L. San Millan, and H. F. Escobar-Morreale Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. Arch Intern Med, October 23, 2006; 166(19): 2081 - 2086. [Abstract] [Full Text] [PDF]

				Z. T. Bloomgarden Third Annual World Congress on the Insulin Resistance Syndrome: Associated conditions. Diabetes Care, September 1, 2006; 29(9): 2165 - 2174. [Full Text] [PDF]

				The ESHRE Capri Workshop Group Hormones and cardiovascular health in women Hum. Reprod. Update, September 1, 2006; 12(5): 483 - 497. [Abstract] [Full Text] [PDF]

				S.K. Blank, C.R. McCartney, and J.C. Marshall The origins and sequelae of abnormal neuroendocrine function in polycystic ovary syndrome Hum. Reprod. Update, July 1, 2006; 12(4): 351 - 361. [Abstract] [Full Text] [PDF]

				R. Pasquali and A. Gambineri Insulin-sensitizing agents in polycystic ovary syndrome. Eur. J. Endocrinol., June 1, 2006; 154(6): 763 - 775. [Abstract] [Full Text] [PDF]

				A. Gambineri, V. Vicennati, S. Genghini, F. Tomassoni, U. Pagotto, R. Pasquali, and B. R. Walker Genetic Variation in 11{beta}-Hydroxysteroid Dehydrogenase Type 1 Predicts Adrenal Hyperandrogenism among Lean Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2295 - 2302. [Abstract] [Full Text] [PDF]

				J. C. Lo, S. L. Feigenbaum, J. Yang, A. R. Pressman, J. V. Selby, and A. S. Go Epidemiology and Adverse Cardiovascular Risk Profile of Diagnosed Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1357 - 1363. [Abstract] [Full Text] [PDF]

				N. I. Leibel, E. E. Baumann, M. Kocherginsky, and R. L. Rosenfield Relationship of Adolescent Polycystic Ovary Syndrome to Parental Metabolic Syndrome J. Clin. Endocrinol. Metab., April 1, 2006; 91(4): 1275 - 1283. [Abstract] [Full Text] [PDF]

				M. E. Zanolin, F. Tosi, G. Zoppini, R. Castello, G. Spiazzi, R. Dorizzi, M. Muggeo, and P. Moghetti Clustering of Cardiovascular Risk Factors Associated With the Insulin Resistance Syndrome: Assessment by principal component analysis in young hyperandrogenic women Diabetes Care, February 1, 2006; 29(2): 372 - 378. [Abstract] [Full Text] [PDF]

				E Carmina, N Napoli, R A Longo, G B Rini, and R A Lobo Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS Eur. J. Endocrinol., January 1, 2006; 154(1): 141 - 145. [Abstract] [Full Text] [PDF]

				D. A. Ehrmann, D. R. Liljenquist, K. Kasza, R. Azziz, R. S. Legro, M. N. Ghazzi, and for the PCOS/Troglitazone Study Group Prevalence and Predictors of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., January 1, 2006; 91(1): 48 - 53. [Abstract] [Full Text] [PDF]

				H. F. Escobar-Morreale, J. I. Botella-Carretero, F. Alvarez-Blasco, J. Sancho, and J. L. San Millan The Polycystic Ovary Syndrome Associated with Morbid Obesity May Resolve after Weight Loss Induced by Bariatric Surgery J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6364 - 6369. [Abstract] [Full Text] [PDF]

				J. Vrbikova, K. Vondra, D. Cibula, K. Dvorakova, S. Stanicka, D. Sramkova, G. Sindelka, M. Hill, B. Bendlova, and J. Skrha Metabolic syndrome in young Czech women with polycystic ovary syndrome Hum. Reprod., December 1, 2005; 20(12): 3328 - 3332. [Abstract] [Full Text] [PDF]

				F. Orio Jr., S. Palomba, T. Cascella, B. De Simone, F. Manguso, S. Savastano, T. Russo, A. Tolino, F. Zullo, G. Lombardi, et al. Improvement in Endothelial Structure and Function after Metformin Treatment in Young Normal-Weight Women with Polycystic Ovary Syndrome: Results of a 6-Month Study J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6072 - 6076. [Abstract] [Full Text] [PDF]

				S. M. Grundy, J. I. Cleeman, S. R. Daniels, K. A. Donato, R. H. Eckel, B. A. Franklin, D. J. Gordon, R. M. Krauss, P. J. Savage, S. C. Smith Jr, et al. Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement Circulation, October 25, 2005; 112(17): 2735 - 2752. [Full Text] [PDF]

				Effects of Polycystic Ovary Syndrome DOC News, July 1, 2005; 2(7): 14 - 14. [Full Text]

				A. Dokras, M. Bochner, E. Hollinrake, S. Markham, B. VanVoorhis, and D. H. Jagasia Screening Women With Polycystic Ovary Syndrome for Metabolic Syndrome Obstet. Gynecol., July 1, 2005; 106(1): 131 - 137. [Abstract] [Full Text] [PDF]

				She Has Acne, but Does She Have HAIR? Journal Watch Dermatology, May 24, 2005; 2005(524): 3 - 3. [Full Text]